Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program

PURPOSE/BACKGROUND: The Phase 3 program for RBP-7000, a once-monthly subcutaneous (SC) extended-release risperidone formulation approved for treatment of schizophrenia, consisted of a double-blind placebo-controlled trial (previously reported) and a 52-week open-label study of monthly RBP-7000 120 m...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Psychopharmacol
Asıl Yazarlar: Andorn, Anne, Graham, Jay, Csernansky, John, Newcomer, John W., Shinde, Sunita, Muma, Gilbert, Heidbreder, Christian, Fava, Maurizio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2019
Konular:
Original Contributions
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6728056/
https://ncbi.nlm.nih.gov/pubmed/31343440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000001076
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller